Change search
ReferencesLink to record
Permanent link

Direct link
Anticompetitive marketing in the Context of Pharmaceutical Switching
Uppsala University, Disciplinary Domain of Humanities and Social Sciences, Faculty of Law, Department of Law. Uppsala University, The Swedish Collegium for Advanced Study in the Social Sciences (SCASSS). (Immaterial- och marknadsrätt)
2013 (English)In: Nordic Perspectives on Competition in Innovation markets / [ed] Hans Henrik Lidgard, Lund: Maria Magle Publishing , 2013, 129-144 p.Chapter in book (Other academic)
Abstract [en]

The article deals with the intersection between competition law rules on abuse of a dominant position and switching strategies employed by pharmaceutical originator companies. Switching is also known as ever-greening, product hopping or product life cycle strategies. It is one of the most topical issues in the patent-antitrust intersection today and consists in launching a slightly modified, second generation pharmaceutical, 1-2 years before the patent exclusivity expires for a first generation product. In this window originators try to migrate patients to a reformulated product. If successful, this will shield the originator from the effects of generic substitution for the first generation product. In the AstraZeneca-case the EU General Court held that a selective redrawal of marketing authorizations for a first generation product was an abuse of a dominant position under article 102 TFEU. This article focuses on other components in a switching strategy, especially the timing and content of marketing efforts by an originator company. Marketing is pro-competitive in almost all cases, but due to the special regulatory context in the pharmaceutical industry, marketing by an originator company can be used in an excluding fashion in the pharmaceutical industry. The conclusion is reached that casting the quality or price of the originator’s first generation product in a bad light, in comparison with the second generation product during exclusivity for the first generation product, may be an abuse by a dominant firm falling foul of article 102 TFEU. It is in effect equivalent to negative comparative advertising messages concerning a competitor’s soon to be launched product.

Place, publisher, year, edition, pages
Lund: Maria Magle Publishing , 2013. 129-144 p.
Keyword [en]
Competition Pharamceutical
National Category
Social Sciences
Research subject
Civil Law
URN: urn:nbn:se:uu:diva-197452ISBN: 978-91-637-2583-8OAI: diva2:612970
Available from: 2013-03-26 Created: 2013-03-26 Last updated: 2013-03-26Bibliographically approved

Open Access in DiVA

Domeij inskickad(230 kB)285 downloads
File information
File name FULLTEXT02.pdfFile size 230 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Search in DiVA

By author/editor
Domeij, Bengt
By organisation
Department of LawThe Swedish Collegium for Advanced Study in the Social Sciences (SCASSS)
Social Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 285 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 292 hits
ReferencesLink to record
Permanent link

Direct link